SecBot SecBot

LBRX

LB PHARMACEUTICALS INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001691082 Biotech & Drug Discovery
$39.17 +0.44 (+1.13%)
Oct 26 4:00 PM ET · prev $38.73
Market cap
$1.3B
Small cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$55.00
+40% · range $35.00–80.00
Next earnings
Nov 5
in 10 days · EPS est. −$1.52
1 year
+134.5%
from $16.70 · Oct 27
30 days
+3.4%
from $37.89
52-week range
$14.61–49.48
−21% from high · low Nov 10
Avg volume 20D
436.8K
shares / day
Short interest
6.01M
≈18.6% of shares · +7.0%
Days to cover
14.5
at average volume
Insider net
+$20.0M
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 7 reports · 90 days
Balance 1 bearish · 2 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 6/7 ·Next Earnings date, Nov 5, 2026
Strongest BEARISH The SEC declared effective LB Pharmaceuticals' registration statement on Form S-3 (File No. 333-294900) on…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $20.0M at an average $26.37. No open-market sales. Price is 49% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 17 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Median target $55.00 (+40%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.930 → −$1.520 over 90 days.

  • Short sellersSTEADY

    Short interest +7.0% to 6.01M shares. 14.5 days to cover, ≈18.6% of shares.

  • TrendDOWNTREND

    7% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GOLDMAN SACHS GROUP INCADD576,456$18.7M
MILLENNIUM MANAGEMENT LLCADD259,219$8.4M
AMERIPRISE FINANCIAL INCDOUBLED227,485$7.4M
CITADEL ADVISORS LLCTRIM215,969$7.0M
VANGUARD PORTFOLIO MANAGEMENT LLCADD152,162$4.9M
BNP PARIBAS FINANCIAL MARKETSDOUBLED86,371$2.8M
UBS Group AGTRIM85,951$2.8M
Nuveen, LLCDOUBLED52,142$1.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy5Buy9Hold1Sell0Strong Sell0
12-month targets · 11 analysts

Price is inside the target range. Median implies +40%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 9, 2026Canaccord Genuity
INITIATE
INITIATEBuy
Oct 6, 2026Guggenheim
INITIATE
INITIATEBuy
Oct 5, 2026Roth Capital
DOWNGRADE
DOWNGRADENeutral
Oct 2, 2026Needham
INITIATE
INITIATEBuy
Aug 24, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 12, 2026BMO Capital
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$20.0M
bought · 1 insider
$0
sold · 0 insiders
+48.6%
vs their $26.37 cost
DateInsiderTypeValue
Oct 9, 2026
Kozauer Susan Gani
Chief Medical Officer
AWARD200,000 sh
Oct 9, 2026
Miller Joseph M
Chief Financial Officer
AWARD200,000 sh
Jul 30, 2026
Deep Track Biotechnology Master Fund, Ltd.
10%+ Owner
BUY$10.0M
Jun 3, 2026
Garland J. Scott
Director
AWARD10,000 sh
Jun 3, 2026
Luse Rebecca
Director
AWARD10,000 sh
Jun 3, 2026
Kane William P Jr
Director
AWARD10,000 sh
Jun 3, 2026
Nussbaum Ran
Director
AWARD10,000 sh
Jun 3, 2026
Lenz Robert A.
Director
AWARD12,500 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
−$1.52
EPS estimate, this quarter
−63%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.52-$1.74–-$1.07+2.8%$0.00
Next Q-$1.52-$1.81–-$1.15+0.9%$0.00
Current FY-$5.47-$5.93–-$4.63+1.2%$0.00
Next FY-$5.13-$6.41–-$4.14-1.9%$0.00

Short side

FINRA· Sep 30, 2026
6,010,646
shares short
+7.0%
vs prior settlement
14.5
days to cover
≈18.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Other
LB Pharmaceuticals to Participate in Upcoming Investor Events
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Com
Oct 13, 2026 SEC
JPMorgan Chase & Co. filed an amended Schedule 13G disclosing beneficial ownership of 1,401,790 shares of LB…
SC 13G/A — Impact 2/10
Oct 9, 2026 Insider
Kozauer Susan Gani was granted 200,000 shares
Chief Medical Officer
Oct 9, 2026 Insider
Miller Joseph M was granted 200,000 shares
Chief Financial Officer
Oct 6, 2026 SEC
The SEC declared effective LB Pharmaceuticals' registration statement on Form S-3 (File No. 333-294900) on October 5…
EFFECT — Impact 5/10
Sep 15, 2026 SEC
LB Pharmaceuticals Inc. filed an 8-K covering Item 5.02 (officer/director departure or appointment), Item 7.01…
8-K — Impact 3/10
Jul 30, 2026 Insider
Deep Track Biotechnology Master Fund, Ltd. bought 286,205 shares
10%+ Owner @ $34.94 ($10.0M)
Jul 22, 2026 Press
LB Pharmaceuticals announced that its pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia is enrolling faster than…
Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
LBRX Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Oct 15, 2026
Press release
LB Pharmaceuticals to Participate in Upcoming Investor Events
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company...
Sep 3, 2026
Press release
LB Pharmaceuticals to Participate in Upcoming September Investor Events
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company…
Aug 11, 2026
Earnings
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027
Jul 22, 2026
FDA
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company…
Jul 10, 2026
Press release
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), today announced that it…

SecBot reports

13 filings · 4 press releases · 3 bullish · 1 bearish · 1 mixed · 8 neutral
All LBRX filing & press-release reports (17)